Infections in Patients Receiving Subcutaneous Biological Treatments for Moderate to Severe Psoriasis by Andrea Messori & Sabrina Trippoli
RESEARCH LETTER
Infections in Patients Receiving Subcutaneous Biological
Treatments for Moderate to Severe Psoriasis
Andrea Messori1,2 • Sabrina Trippoli1
Published online: 2 September 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
In a previous study, we evaluated the safety of biological
drugs in the treatment of moderate to severe psoriasis [1]
and we found a quite favourable profile for these agents
(adalimumab, ustekinumab and etanercept). More recently,
a systematic review [2] has found an increase in the inci-
dence of serious infections in patients with rheumatoid
arthritis treated with biological agents. To re-evaluate this
issue, we carried out an updated analysis (Analysis 1) in
which we included the data of the most recently approved
agent for this indication (i.e. secukinumab). Furthermore,
we performed a Bayesian meta-regression analysis (Anal-
ysis 2; temporal trend analysis) to investigate whether the
incidence of infections has undergone any changes from
2000 to 2015.
Our updated literature search, based on PubMed, cov-
ered the previous 15 years and included only randomized
controlled trials (see also Fig. S1 in the Supplementary
Material and the PRISMA schematic of our search). In
comparison with the search carried out for our previous
study, the main difference was that secukinumab was also
included among the agents evaluated for safety. In Analysis
1, we employed the same Bayesian network meta-analysis
[3–5] as in our previous report, but the outcome measure
was the odds ratio (rather than the risk difference) because
in this way our results were comparable to those published
by Singh et al. [2]. In Analysis 2, we employed a meta-
regression model based on the same Bayesian approach [6],
in which the covariate (calendar year) was handled as a
continuous variable. All the Bayesian models adopted for
our analyses [3–6] have been developed by the National
Institute for Health and Care Excellence Support Unit (UK)
and are available as a fixed-effects model and a random-
effects model. In both analyses, we employed the random-
effects model (which is more conservative) because we
anticipated the presence of heterogeneity. All statistical
calculations were performed using the software package
WinBUGS 1.4.3 (Cambridge, UK).
Our literature search extracted a total of 121 eligible
citations. We excluded 95 citations on the basis of the
abstract or the title. We then examined the full text of the
remaining 26 articles and we finally selected a total of 13
randomized controlled trials that met our inclusion criteria.
Of these 13 studies, two evaluated adalimumab, five
ustekinumab (45 and 90 mg), four low- and high-dose
etanercept and two secukinumab (150 and 300 mg). All of
these trials adopted a double-blind design and analysed the
safety of these treatments in terms of any infectious
adverse event. Table 1 illustrates the raw data of infection
incidence, extracted from these 13 trials.
Figure 1 shows the results of Analysis 1 focused on the
incidence of any infectious adverse event. The analysis
generated seven direct comparisons between an active
agent (adalimumab, ustekinumab 45 mg, ustekinumab 90
mg, high-dose etanercept, low-dose etanercept, secuk-
inumab 150 mg or secukinumab 300 mg) and placebo and
17 indirect comparisons between the active agents in all
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possible combinations. Because all the indirect compar-
isons were little informative, Fig. 1 has been restricted to
the direct comparisons, which however were very far from
demonstrating any difference. Analysis 2 (temporal trend
analysis) found a regression coefficient close to 0 (value:
?0.0336; 95 % credible interval -0.219 to 0.283); this
result identifies a flat (i.e. approximately horizontal) meta-
regression line that fails to suggest any effect of time on the
risk of infection related to biologic drugs. Because the risk
of infection is not likely to depend on the patients’ disease
condition (rheumatoid arthritis or psoriasis), further studies
are needed to shed light on this controversial issue.
In conclusion, our results provided a synthesis of the
information currently available from randomized trials
concerning the risk of infections attributable to biological
agents in patients with moderate to severe psoriasis. All
biological agents currently approved in Europe were tested.
Interestingly enough, while in their study on rheumatoid
arthritis Singh et al. [2] found a significantly increased risk
of infections in the direct comparisons between biological
Table 1 Incidence of any infectious adverse event in 13 randomized trialsa
Study
no.







1 Menter et al. (2008) 89 398 Placebo At week 16
1 Menter et al. (2008) 235 814 Adalimumab
2 Asahina et al. (2010) 23 46 Placebo At week 24
2 Asashina et al. (2010) 18 43 Adalimumab
3 Papp et al. (2008) 82 410 Placebo At week 12
3 Papp et al. (2008) 88 409 Ustekinumab 45 mg
3 Papp et al. (2008) 92 411 Ustekinumab 90 mg
4 Igarashi et al. (2012) 6 32 Placebo At week 12
4 Igarashi et al. (2012) 13 64 Ustekinumab 45 mg
4 Igarashi et al. (2012) 15 62 Ustekinumab 90 mg
5 Leonardi et al. (2008) 68 255 Placebo At week 12
5 Leonardi et al. (2008) 80 255 Ustekinumab 45 mg
5 Leonardi et al. (2008) 66 255 Ustekinumab 90 mg
6 Tsai et al. (2011) 14 60 Placebo At week 12
6 Tsai et al. (2011) 20 61 Ustekinumab 45 mg
7 Zhu et al. (2013) 31 161 Placebo At week 12
7 Zhu et al. (2013) 41 160 Ustekinumab 45 mg
8 Tyring et al. (2006) 71 306 Placebo At week 12
8 Tyring et al. (2006) 87 312 HDE
9 Papp et al. (2005) 25 193 Placebo At week 12
9 Papp et al. (2005) 26 196 LDE
9 Papp et al. (2005) 75 194 HDE
10 Leonardi et al. (2003) 19 166 Placebo At week 12
10 Leonardi et al. (2003) 16 160 LDE
10 Leonardi et al. (2003) 9 164 HDE
11 Van de Kerkhof et al. (2008) 12 46 Placebo At week 24
11 Van de Kerkhof et al. (2003) 17 96 HDE
12 FIXTURE (2014) 163 327 Placebo At week 12
12 FIXTURE (2014) 101 327 Secukinumab 150 mg
12 FIXTURE (2014) 87 326 Secukinumab 300 mg
13 ERASURE (2014) 40 248 Placebo At week 12
13 ERASURE (2014) 66 245 Secukinumab 150 mg
13 ERASURE (2014) 72 245 Secukinumab 300 mg
HDE high-dose etanercept, LDE low-dose etanercept
a Table S1 in the Supplementary Material provides the full bibliographic details of the 13 trials included in our analysis
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agents and controls, our results from patients with psoriasis
did not suggest any such conclusion.
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Fig. 1 Endpoint of any infectious adverse event. Forest plot of the
values of odds ratios (with 95 % credible intervals) calculated for
seven direct comparisons of active agents vs. controls according to the
Bayesian random-effects model. ADA adalimumab, U45 ustekinumab
45 mg, U90 ustekinumab 90 mg, HDE high-dose etanercept, LDE
low-dose etanercept, SEC150 secukinumab 150 mg, SEC300 secuk-
inumab 300 mg
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